New Brunswick, New Jersey
April 24, 2002

Senesco Technologies, Inc. ("Senesco" or the "Company")(OTC BB: SENO), announced today that it has closed its ongoing private placement of restricted equity securities.

The final $350,000 raised through the private placement of the Company's restricted equity securities with certain accredited investors was received on April 17, 2002. This portion of the financing consisted of 200,000 shares of Common Stock, warrants to purchase 43,750 shares of Common Stock with an exercise price of $2.00 per share and warrants to purchase an additional 43,750 shares of Common Stock with an exercise price of $3.25 per share. The Company raised a total of $3,477,500 in this financing.

Senesco (OTC BB: SENO) takes its name from the scientific term for the aging of cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that Senesco's technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has begun to explore ways to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Senesco partners with leading-edge companies and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and has research laboratories at the University of Waterloo in Ontario, Canada.